Ariana Pelosci

Articles

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma

June 3rd 2025

Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.

Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer

June 2nd 2025

Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.

First-Line T-DXd Plus Pertuzumab Yields PFS Benefit in HER2+ Advanced Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.

Adagrasib Plus Pembrolizumab Generates Responses in KRAS G12C+ NSCLC

June 1st 2025

Adagrasib plus pembrolizumab was efficacious in patients with KRAS G12C-mutant NSCLC.

Postoperative Nivolumab Plus SOC Extends DFS in Resected, High-Risk Head and Neck Cancer

June 1st 2025

Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.

T-DXd Maintains Efficacy in HR+/HER2-Low or HER2-Ultralow Breast Cancer Irrespective of Mutational Subtype

June 1st 2025

T-DXd maintained efficacy in HR-positive, HER2-low or -ultralow metastatic breast cancer irrespective of mutational subtype.

Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism

May 31st 2025

Amivantamab/chemotherapy demonstrated sustained efficacy, despite the osimertinib resistance mechanism in patients with EGFR-mutated NSCLC.

Imulunestrant With/Without Abemaciclib Generates Improved PROs in ER+/HER2– Advanced Breast Cancer

May 31st 2025

Patient-reported outcomes revealed that imulunestrant with or without abemaciclib was favored vs SOC in ER-positive, HER2-negative breast cancer.

ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer

May 31st 2025

Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.

GLP-1 Agonists Are Linked to Modest Decrease in Obesity-Related Cancers in Adults With Diabetes

May 22nd 2025

The use of GLP-1 agonists was not associated with higher cancer rates and led to a decrease in obesity-related cancers in adults with diabetes.

CAR T-Cell Therapy Shows Consistent Efficacy Across Age Groups in R/R LBCL

March 25th 2025

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL

March 23rd 2025

The risk of developing ICANS with CAR T-cell therapy was higher in patients with NHL who experienced a recent fall and could not balance on their left leg.

Residential-Specific Factors and ADT Use Influence HRQOL Outcomes in Bladder and Prostate Cancer

March 22nd 2025

Adjuvant HRQOL outcomes improved in patients with bladder cancer living in rural areas and were worse with ADT plus radiotherapy after prostatectomy.

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

March 17th 2025

Maintenance selinexor improved progression-free survival in TP53 wild-type advanced endometrial cancer.

Metformin With IUD Boosts Responses in EIN and Endometrial Cancer

March 17th 2025

Patients with endometrial cancer had slightly higher CR rates with metformin plus a levonorgestrel-releasing IUD vs historical data with the IUD alone.

Avutometinib With Defactinib Exceeds Response Threshold in Advanced Mesonephric Gynecologic Cancer

March 16th 2025

The combination of avutometinib and defactinib has previously shown activity in patients with low-grade serous ovarian cancer.

Pembrolizumab Plus Olaparib Improves PFS in BRCA Wild-Type Ovarian Cancer

March 16th 2025

The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.

Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer

March 15th 2025

The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.

Analyses Show Effects of Treatment, Patient Location on HRQOL in Bladder and Prostate Cancer

March 1st 2025

HRQOL results were evaluated in rural patients with bladder cancer and prostate cancer following ADT treatment and postoperative radiotherapy.

Cabozantinib Plus Nivolumab/Ipilimumab Sustains PFS Benefit in Advanced RCC

February 15th 2025

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.